UCB’s bimekizumab data in plaque psoriasis published in The Lancet
Phase III BE VIVID and BE READY studies both met their co-primary endpoints
Read More
Tag: The Lancet
New data shows steep rise in people waiting for cancer tests
CR UK data also shows 2.3 million fewer tests have taken place compared to a year ago
Read More
The Lancet retracts study linking hydroxychloroquine with deaths
The study linked the drug with higher death rates in patients with COVID-19
Read More
Cervical cancer eradication a possibility, finds new report
After five to eight years of vaccination, the prevalence of HPV 16 and 18 decreased significantly by 83% in girls aged 13 to 19 years.
Read More
Trial finds higher aspirin bleed risk for elderly
The use of daily aspirin as a blood thinner in people aged over 75 years is linked with a much higher risk of major and potentially fatal stomach bleeds than previously thought.
Read More
UK researchers find evidence of ‘nocebo’ effect for statins
Patients report more side effects when they know they are taking a statin than when don’t, according to findings of a recent study led by researchers at Imperial College London, funded by Pfizer, and published in The Lancet.
Read More
Bowel scope screening cuts cancer and death rate
A one-off screening test called Bowel Scope cuts the risk of developing bowel cancer by more than one third and could save thousands of lives, according to a new study published in The Lancet.
Read More
Group calls for radical new approach to UK health
A distinguished group of experts that includes clinicians, scientists, social entrepreneurs and crossbench peers is calling for a radical rethink on health in the UK as the National Health Service “lurches from crisis to crisis” against a backdrop of Brexit.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
